Review on the occasion of a decade of recombinant human TSH: Prospects and novel uses

Thyroid

Volumn 18, Issue 5, 2008, Pages 509-516

  Duntas, Leonidas H ^a   Cooper, David S ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

ADIPOCYTE; AGING; CLINICAL TRIAL; HUMAN; HYPOTHYROIDISM; LYMPHOCYTE; NODULAR GOITER; OSTEOCYTE; PRIORITY JOURNAL; REVIEW; THYROID CANCER;

GOITER; HUMANS; HYPOTHYROIDISM; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 43449086398     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0331     Document Type: Review

References (81)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
2. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Sherman SI, Tuttle RM; The American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patient with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
5. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
6. Goldman JM, Line BR, Aamodt RL, Robins J 1980 Influence of triiodothyronine withdrawal time on 131-I uptake post-thyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50:734-739.
7. Ladenson PW 2000 Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30:98-106.
8. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645.
9. Mazzaferri EL, Kloos RT 2000 Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 10:767-778.
10. Kohlfuerst S, Igerc I, Lind P 2005 Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 15:371-376.
11. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
12. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625.
13. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
14. Smith PE, Smith IP 1922 The repair and activation of the thyroid in the hypophysectomized tadpole by the parenteral administration of fresh anterior lobe of the bovine hypophysis. J Med Res 43:267-273.
15. Liao TH, Pierce JG 1971 The primary structure of bovine thyrotropin II. The amino acid sequences and the reduced, s-carboxyl-methyl alpha and beta chains. J Biol Chem 246:850-853.
16. Magner JA 1990 Thyroid-stimulating hormone: biosynthesis, cell biology and bioactivity. Endocr Rev 11:354-385.
17. Wondisford FE, Usala SJ, DeCherney GS, Castren M, Radovick S, Gyves PW, Tremple JP, Kerfoot BP, Nikodem VM, Carter BJ, Weintraub BD 1998 Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. Mol Endocrinol 2:32-39.
18. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt MB, Weintraub BD 1991 Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 128:341-348.
19. Szkudlinski MW, Thotakura NR, Bucci I, Joshi LR, Tsai A, East-Palmer J, Shiloach J, Weintraub BD 1993 Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 133:1490-1502.
20. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, Curran P, McEllin K, Reynolds J, Robbins J, Weintraub BD 1994 Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78:188-196.
21. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DR, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896.
22. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, Reiners C 2003 Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 31:924-925.
23. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F, Panico A, Lupoli G 2003 Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 88:1319-1322.
24. Montesano T, Durante C, Attard M, Crocetti U, Meringolo D, Bruno R, Tumino S, Rubello D, Al-Nahhas A, Colandrea M, Maranghi M, Travascio L, Ronga G, Torlontano M 2007 Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed Pharmacother 61:468-471.
25. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM 2005 Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 90:6553-6555.
26. Huber GK, Fong P, Concepcion ES, Davies TF 1991 Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 72:1328-1331.
27. Braverman LE, Pratt BM, Ebner S, Longcope C 1992 Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 74:1135-1139.
28. Ramirez L, Braverman LE, White B, Emerson CH 1997 Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 82:2836-2839.
29. Emerson CH, Torres MS 2003 Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses. BioDrugs 17:19-38.
30. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross D, Luster M, Samuels M, Becker DV, Maxon III HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub B, Ridgway C 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
31. Ladenson PW 2000 Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30:98-106.
32. Mazzaferri EL, Massoll N 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 9:227-247.
33. Robbins RJ, Robbins AK 2003 Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 88:1933-1938.
34. Woodmansee WW, Haugen BR 2004 Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf) 61:163-173.
35. Schlumberger M, Ricard M, de Pouvourville G, Pacini F 2007 Howthe availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab 3:641-650.
36. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651-659.
37. Duntas LH, Biondi B 2007 Short-term hypothyroidism after levothyroxine withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 156:13-19.
38. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW 2006 A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878-884.
39. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869.
40. Berg G, Lindstedt G, Suurküla M, Jansson S 2002 Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25:44-52.
41. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubiniecka B, Hesse-Lazar K, Turska M, Zajusz A 2003 Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: single-center study of 54 patients. Eur J Nucl Med Mol Imaging 30:1077-1086.
42. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Richard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
43. Luster M, Felbinger R, Dietlein M, Reiners C 2005 Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15:1147-1155.
44. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, de Pouvourville G 2007 Sick leave for follow-up in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 156:531-538.
45. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654.
46. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poqqiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Capri C, Pacini F 2007 A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 3:3542-3546.
47. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
48. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2007 Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab [E-pub ahead of print].
49. 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 82:11-14.
50. Luster M, Lippi F, Jarzab B, Perros P, Lassman M, Reiners C, Pacini F 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49-64.
51. Robbins RJ, Driedger A, Magner J; U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group 2006 Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121-1130.
52. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F 2001 Radioiodine treatment of differentiated thyroid cancer on l-thyroxine plus recombinant human TSH (rhTSH): initial single-center experience. Eur J Endocrinol 144:5-11.
53. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubieniecka B, Hasse-Lazar K, Turska M, Zajusz A 2003 Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 30:1077-1086.
54. Potzi C, Moameni A, Karanikas G, Preifellner J, Becherer A, Pirich C, Dudczak R 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 65:519-523.
55. Braga M, Ringel MD, Cooper DS 2001 Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 86:5148-5151.
56. Schlumberger M, Ricard M, Pacini F 2000 Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 143:557-563.
57. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P 2004 Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91-95.
58. 131I-negative papillary thyroid carcinoma. Thyroid 16:267-272.
59. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA 2001 Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 86:5330-5336.
60. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, Schellekens AP, Bus JW, Bravenboer B, Hermus AR 2000 Administration of single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in non-toxic nodular goiter. J Clin Endocrinol Metab 85:3592-3596.
61. Albino CC, Mesa Junior CO, Olandowski M, Ueda CE, Woellner LC, Goedert CA, Souza AM, Graf H 2005 Recombinant human TSH (rhTSH) as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 90:2775-2780.
62. Duick DS, Baskin HJ 2003 Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of non-toxic and toxic multinodular goiters. Endocr Pract 9:204-209.
63. Silva MN, Rubio IG, Romao R, Gebrin EM, Buchpiquel C, Tomimori E, Camargo R, Cardia MS, Medeiros-Neto G 2004 Administration of a single dose of recombinant human thyrotropin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 60:300-308.
64. Cohen O, Ilany J, Hoffman C, Olchovsky D, Dabhi S, Karasik A, Goshen E, Rotenberg G, Zwas ST 2006 Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 154:243-252.
65. Giusti M, Cappi C, Santaniello B, Ceresola E, Augeri C, Lagasio C, Minuto F 2006 Safety and efficacy of administering 0.2mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter. Minerva Endocrinol 31:191-209.
66. Nielsen VE, Bonnema SJ, Boel-Joergensen H, Grupe P, Hegedus L 2006 Stimulation with 0.3mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 166:1476-1482.
67. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, Grupe P, Andersen PB, Basholt L, Hegedus L 2007 Improvement of goiter volume reduction following 0.3mg rhTSH stimulated radioiodine therapy in patients with a very large goiter: a double-blinded randomized trial. J Clin Endocrinol Metab 92:3424-3428.
68. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, Woellner LC, Goedert CA, Boquszewski CL, Carvalho GA, Graf H 2007 Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 40:1661-1670.
69. Nielsen VE, Bonnema SJ, Hegedus L 2006 Transient goiter enlargement after administration of 0.3mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 91:1317-1322.
70. Fugazzola L, Persani L, Mannavola D, Reschini E, Vannucchi G, Weber G, Beck-Peccoz P 2003 Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol 59:230-236.
71. Fugazzola L, Persani L, Vannucchi G, Carletto M, Mannavola D, Vigone MC, Cortinovis F, Beccaria L, Longari V, Weber G, Beck-Peccoz P 2007 Thyroid scintigraphy and perchlorate test after recombinant human TSH: a new tool for the differential diagnosis of congenital hypothyroidism during infancy. Eur J Nucl Med Mol Imaging 34:1498-1503.
72. Tiosano D, Even L, Shen Orr Z, Hochberg Z 2007 Recombinant thyrotropin in the diagnosis of congenital hypothyroidism. J Clin Endocrinol Metab 92:1434-1437.
73. Novack D 2003 TSH: the bone suppressing hormone. Cell 115:129-130.
74. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C 2005 Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20:480-486.
75. Hase H, Ando T, Eldeiry L, Brebene A, Liu Y, Amano H, Davies TF, Sun L, Zaidi M 2005 TNFa mediates the skeletal effects of thyroid stimulating hormone. Proc Natl Acad Sci USA 103:12849-12854.
76. Marcus C, Ehren H, Bolme P, Amer P 1988 Regulation of lipolysis during the neonatal period: importance of thyrotropin. J Clin Invest 82:1793-1797.
77. Chang TC, Wu SL, Hsiao YL, Kuo ST, Chien LF, Kuo YF, Change CC, Chang TJ 1994 TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor. Clin Immunol Immunopathol 71:113-120.
78. Du Villard JA, Wicker R, Crespo P, Russo D, Filetti S, Gutkind JS, Sarasin A, Suárez HG 1994 Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. Oncogene 19:4896-4905.
79. Balzan S, Nicolini G, Forini F, Boni G, Del Carratore R, Nicolini A, Carpi A, Iervasi G 2007 Presence of a functional TSH receptor on human erythrocytes. Biomed Pharmacother 61:463-467.
80. Antunes TT, Gagnon A, Chen B, Pacini F, Smith TJ, Sorisky A 2006 Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot. Am J Physiol Endocrinol Metab 290:1140-1144.
81. Harbour DV, Kruger TE, Coppenhaver D, Smith EM, Meyer WJ 1989 Differential expression and regulation of thyrotropin (TSH) in T cell lines. Mol Cell Endocrinol 64:229-241.